Incidence of WHO grade-3 to grade-4 side effects during induction therapy
. | Group A, G-CSF-/- . | Group B, G-CSF+/- . | Group C, G-CSF-/+ . | Group D, G-CSF+/+ . |
|---|---|---|---|---|
| N | 178 | 172 | 173 | 177 |
| Hemorrhage | 9 (5.0) | 15 (8.8) | 13 (7.5) | 7 (4.0) |
| Hepatic | 14 (7.9) | 13 (7.5) | 21 (12.1) | 22 (12.4) |
| Cardiovascular* | 23 (12.9) | 11 (6.4) | 15 (8.7) | 20 (11.3) |
| Hypotension | 2 (1.1) | 2 (1.2) | 8 (4.6) | 7 (4.0) |
| Diarrhea | 10 (5.6) | 3 (1.8) | 8 (4.6) | 7 (4.0) |
| Nausea | 38 (21.4) | 40 (23.3) | 30 (17.4) | 28 (15.8) |
| Rigors/chills | 0 (0) | 0 (0) | 2 (1.2) | 1 (0.6) |
| Bone pain | 1 (0.6) | 0 (0) | 1 (0.6) | 2 (1.1) |
| Rash/itch | 2 (1.1) | 4 (2.3) | 6 (3.5) | 7 (4.0) |
| Infection | 48 (27.0) | 57 (23.1) | 54 (31.2) | 45 (25.4) |
. | Group A, G-CSF-/- . | Group B, G-CSF+/- . | Group C, G-CSF-/+ . | Group D, G-CSF+/+ . |
|---|---|---|---|---|
| N | 178 | 172 | 173 | 177 |
| Hemorrhage | 9 (5.0) | 15 (8.8) | 13 (7.5) | 7 (4.0) |
| Hepatic | 14 (7.9) | 13 (7.5) | 21 (12.1) | 22 (12.4) |
| Cardiovascular* | 23 (12.9) | 11 (6.4) | 15 (8.7) | 20 (11.3) |
| Hypotension | 2 (1.1) | 2 (1.2) | 8 (4.6) | 7 (4.0) |
| Diarrhea | 10 (5.6) | 3 (1.8) | 8 (4.6) | 7 (4.0) |
| Nausea | 38 (21.4) | 40 (23.3) | 30 (17.4) | 28 (15.8) |
| Rigors/chills | 0 (0) | 0 (0) | 2 (1.2) | 1 (0.6) |
| Bone pain | 1 (0.6) | 0 (0) | 1 (0.6) | 2 (1.1) |
| Rash/itch | 2 (1.1) | 4 (2.3) | 6 (3.5) | 7 (4.0) |
| Infection | 48 (27.0) | 57 (23.1) | 54 (31.2) | 45 (25.4) |
Results are presented as absolute numbers, with the percentages in parentheses.
-/-, indicates not administered on days 1 to 7; +/-, administered on days 1 to 7; -/+, not administered on days 8 to 28; and +/+, administered on days 8 to 28.
Includes nonspecific cardiac events and dysrhythmias.